<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="150989">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134549</url>
  </required_header>
  <id_info>
    <org_study_id>KAI-4169-001</org_study_id>
    <nct_id>NCT01134549</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Rising Single Intravenous Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KAI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nucleus Network Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KAI Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and tolerability of KAI-4169 in
      healthy young males.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of rising single doses of KAI-4169 by IV injection in healthy male subjects</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of rising single doses of KAI-4169 by IV injection in healthy male subjects</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of rising single doses of KAI-4169 by IV injection in healthy male subjects</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hyperparathyroidism, Secondary</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomly assigned to KAI-4169 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAI-4169</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomly assigned to KAI-4169 or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAI-4169</intervention_name>
    <description>Single IV injection 0.2, 2, 5, 10, 20, 40, or 60 mg</description>
    <arm_group_label>KAI-4169</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Single IV injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male between 18 and 45 years of age who have provided written informed consent

          -  Subject is judged to be in good health based on medical history, physical
             examination, and routine laboratory tests

        Exclusion Criteria:

          -  History or presence of any significant acute or chronic illness (e.g.,
             cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine,
             immunologic, dermatologic, or neurologic disease) according to the investigator

          -  History of any ongoing medical condition requiring treatment with prescription
             medication

          -  History of asthma, severe allergies including skin reactions or prior anaphylactic
             type reactions

          -  Clinically significant abnormalities on screening clinical examination or laboratory
             safety tests

          -  History of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Bell, MD</last_name>
    <role>Study Director</role>
    <affiliation>KAI Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <lastchanged_date>August 20, 2010</lastchanged_date>
  <firstreceived_date>May 28, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Karen Pickthorn, Senior Director Clinical Development</name_title>
    <organization>KAI Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Phase 1 Clinical Trials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
